To Establish Whether Individuals With Premenstrual Dysphoric Disorder (PMDD) Demonstrate a Different Luteal-phase Sex Hormone Profile and Ratio Compared With Asymptomatic Controls.
연구 개요
상태
상세 설명
Premenstrual dysphoric disorder (PMDD) is a severe cyclical disorder characterised by affective, cognitive and physical symptoms occurring during the luteal phase of the menstrual cycle and resolving shortly after the onset of menstruation. Although circulating ovarian hormone concentrations are generally considered to be within physiological reference ranges, increasing evidence suggests that altered sensitivity to normal hormonal fluctuations, rather than absolute hormone concentrations alone, may contribute to symptom development.
The progesterone-to-oestradiol ratio has been proposed as a potential biological marker of luteal hormonal balance; however, this has not been systematically evaluated in individuals with PMDD compared with asymptomatic controls.
This observational case-control study will compare serum progesterone concentrations, serum oestradiol concentrations, and the progesterone-to-oestradiol ratio during the mid-luteal phase between participants with PMDD and healthy controls. Hormone measurements will be obtained following confirmation of ovulation using a urinary luteinising hormone (LH) surge, with blood sampling performed approximately seven days after the LH surge to standardise assessment within the mid-luteal phase.
The findings will provide preliminary evidence regarding whether alterations in the progesterone-to-oestradiol ratio are associated with PMDD and may inform future mechanistic studies investigating the endocrine basis of the disorder.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Milli Raizada, MBCHB Hons
- 전화번호: +44 (0)1524 65201
- 이메일: m.raizada2@lancaster.ac.uk
연구 장소
-
-
Lancashire
-
Lancaster, Lancashire, 영국, LA1 4YW
- 모병
- Lancaster University
-
연락하다:
- Milli Raizazda, MBCHB Hons
- 전화번호: +44 (0)1524 65201
- 이메일: m.raizada2@lancaster.ac.uk
-
연락하다:
- Chris Gaffney, BSc (Hons.) MSc PhD SFHEA
- 전화번호: +44 (0)1524 65201
- 이메일: c.gaffney@lancaster.ac.uk
-
수석 연구원:
- milli raizada, MBCHB Hons
-
부수사관:
- chris gaffney, BSc (Hons.) MSc PhD SFHEA
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
건강한 자원 봉사자를 받아들입니다
샘플링 방법
연구 인구
설명
Inclusion criteria
- Aged 18-45 years old (adults but less than the typical perimenopausal age so there is not added bias/variable)
- Regular menstrual cycles (21-35 days for the last 3 months)
- Willing and able to complete a questionnaire (no new clinical diagnosis given)
- Use home urine LH test strips to detect ovulation
- Attend a single in person on site in Lancaster mid luteal blood test sample appointment (approx 7 days post LH surge)
- Provide written informed consent
- Have sufficient English language skills to understand the patient information
- Be either in Group 1 or group 2 Group 1 (PMDD group ie case group) - self reported prior diagnosis of PMDD made by a healthcare professional (GP, psychiatrist, gynaecologist) Group 2 (Control group ie comparison group) - no prior diagnosis of PMDD made by a healthcare professional and no history of clinically significant premenstrual mood symptoms on screening
Exclusion criteria
- Current use or use in the last 3 months of hormonal contraception such as the combined oral contraceptive pill, the progestogen only pill, the implant, the injection, hormonal coil (Mirena, Kyleena) or patch/ring.
- Current use or use in the last 3 months of any hormone replacement therapy (e.g. combined oestrogen and progesterone, oestrogen and Mirena coil combination, oestrogen alone if had a hysterectomy, or progesterone alone) or GnRH analogues use
- On a selective serotonin reuptake inhibitor (SSRI) with a recent initiation or dose change within the last 3 months
- Pregnant, breastfeeding or within 3 months post partum
- Irregular menstrual cycles (outside the 21-35 day window)
- Surgical menopause
- Premature ovarian insufficiency
- Other endocrine disorders e.g. uncontrolled thyroid disease, high prolactin, cushing's syndrome, polycystic ovarian syndrome)
- Regular systemic steroid use or use of other medications known to affect sex hormone within the last 3 months
- Severe mental health issues that impair consent or participation
- Needle phobic so that venepuncture is intolerable
- The use of the emergency contraceptive pill either 3 months prior to the study or during the study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
|---|
|
control group
oestrogen and progesterone levels and ratios 5-7 days post ovulation
|
|
PMDD group
oestrogen and progesterone levels and ratios 5-7 days post ovulation
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
blood level
기간: 5-7 days post ovulation
|
progesterone
|
5-7 days post ovulation
|
|
blood level
기간: 5-7 days post ovulation
|
oestrogen
|
5-7 days post ovulation
|
|
blood test
기간: 5-7 days post ovulation
|
progesterone to oestrogen level
|
5-7 days post ovulation
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Chris Gaffney, BSc (Hons.) MSc PhD SFHEA, Lancaster University
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- v1.9.9.3 20250922
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .